TIDMHCM

RNS Number : 5098T

Hutchison China Meditech Limited

26 March 2021

2020 Annual Report and Notice of Annual General Meeting

Hong Kong, Shanghai, & Florham Park, NJ: Friday, March 26, 2021: Hutchison China MediTech Limited (" HUTCHMED ") (Nasdaq/AIM: HCM) today announces that its 2020 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy ("AGM Materials") have been posted to Shareholders of HUTCHMED ("Shareholders"). The documents can be accessed from the HUTCHMED website ( www.hutch-med.com ).

The 2021 Annual General Meeting ("AGM") will be held at the Conference Room, 18th Floor, Hutchison Telecom Tower, 99 Cheung Fai Road, Tsing Yi, Hong Kong on Wednesday, April 28, 2021 at 6:00 pm Hong Kong Time (11:00 am London Time; 6:00 am Eastern Time).

To safeguard the health and safety of Shareholders, HUTCHMED encourages Shareholders to: (i) attend the AGM online and vote by means of electronic facilities; or (ii) exercise their right to vote at the AGM by appointing the Chairman of the AGM as their proxy instead of attending the AGM in person. Shareholders will be able to view a live webcast of the AGM through the website of the Company at https://www.hutch-med.com/event/ . Along with the AGM Materials, all registered Shareholders will also receive a letter containing log in details and information on how to access the webcast.

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM) is an innovative, commercial-stage, biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has advanced ten cancer drug candidates from discovery into clinical studies around the world and has an extensive commercial infrastructure in its home market of China. For more information, please visit: www.hutch-med.com.

CONTACTS

 
Investor Enquiries 
   Mark Lee, Senior Vice President                              +852 2121 8200 
   Annie Cheng, Vice President                                  +1 (973) 567 3786 
 Media Enquiries 
   Americas - Brad Miles, Solebury Trout                        +1 (917) 570 7340 (Mobile) 
                                                                 bmiles@troutgroup.com 
   Europe - Ben Atwell / Alex Shaw, FTI Consulting              +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 
                                                                7779 545 055 (Mobile) 
                                                                HUTCHMED@fticonsulting.com 
   Asia - Joseph Chi Lo / Zhou Yi, Brunswick                    +852 9850 5033 (Mobile) / +852 9783 6894 (Mobile) 
                                                                 HUTCHMED@brunswickgroup.com 
Nominated Advisor 
   Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) 
    Limited                                                     +44 (20) 7886 2500 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ACSSEDFFIEFSEED

(END) Dow Jones Newswires

March 26, 2021 03:00 ET (07:00 GMT)